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Vascular disrupting agents (VDAs) have emerged as anovel antiangiogenic approach to treating lung cancer. At
the 10th annual “Targeted Therapies of The Treatment of
Lung Cancer” meeting in Santa Monica, Dr. Amir Onn
provided a brief overview of VDAs and their potential role in
lung cancer treatment. His introduction was followed by
discussion of three specific VDAs in various stages of clinical
development and mention of other related mediators of an-
giogenesis that may serve as new therapeutic targets in
non-small cell lung cancer (NSCLC).
Angiogenesis inhibitors, such as bevacizumab, inhibit
the formation of new blood vessels in tumors, in addition to
promoting remodeling of existing tumor vasculature, whereas
VDAs target endothelial cells and pericytes of the already
established tumor vasculature. Because tumor blood vessels
are structurally and functionally abnormal, VDAs can selec-
tively target tumor vasculature by several pathways, inhibit-
ing blood flow and causing extensive secondary necrosis
within tumors while leaving normal tissue relatively intact.1
There are currently two types of VDAs that are in preclinical
and clinical development, including small molecules and
ligand-directed VDAs. The small molecule VDAs can be
further divided into two groups: the tubulin-binding agents
and the flavonoids. The testing of VDAs in clinical trials is
ongoing and will help define their role in the treatment of
NSCLC.
SUMMARY OF PRESENTATIONS
Dr. Primo Lara discussed ASA-404 (5,6-dimethylxan-
thenone-4 acetic acid), a flavonoid, which acts by disrupting
the actin cytoskeleton of tumor vascular endothelial cells
through both indirect and direct mechanisms of action. The
indirect action is associated with release of tumor necrosis
factor- and other cytokines and chemokines, which can be
enhanced when ASA-404 is used in combination with other
chemotherapy.2 The direct action results in vascular endothe-
lial cell apoptosis independent of tumor necrosis factor-
induction.3 In lung cancer xenograft models, ASA-404 was
found to produce antitumor effects when given in combina-
tion with paclitaxel, cisplatin/carboplatin, or gemcitabine.4 In
the early clinical development of ASA-404, two dose-esca-
lation trials and one safety study were conducted, which led
to phase II testing of the agent in the first-line setting of
advanced NSCLC. Results of phase II testing revealed that
patients receiving carboplatin/paclitaxel alone had a median
time to progression of 4.4 months, when compared with 5.4
months when ASA 404 was given in combination with
chemotherapy. Safety profiles were similar between the two
groups with most adverse events attributed to standard ther-
apy. Median overall survival was also prolonged in those
patients receiving ASA 404 (14.9 months) versus those who
received chemotherapy alone (8.8 months).5 On further anal-
ysis, the safety and efficacy of ASA 404 did not vary with
histology, with ASA 404 being generally well tolerated in
both squamous and nonsquamous patients.6 These encourag-
ing results led to the ATTRACT-1 phase III study investi-
gating carboplatin/paclitaxel  ASA 404 in first-line ad-
vanced NSCLC and the ATTRACT-2 phase III study of
docetaxel  ASA 404 in second-line advanced NSCLC.
Dr. Edward Garon discussed fosbretabulin (CA4P), a
tubulin depolymerizing agent, derived from the African Bush
Willow Combretum caffrum. It selectively disrupts the vas-
cular endothelial cell junctional protein, VE-cadherin, target-
ing only those cells that are newly formed and that lack
smooth muscle contact (including abnormal blood vessels).7
Preclinical data suggest that fosbretabulin can enhance the
efficacy of carboplatin/paclitaxel8 and that it can be synergis-
tically combined with bevacizumab with minimal increase in
toxicity,9 which has led to the ongoing FALCON phase II
trial. FALCON is the first randomized study combining an
antiangiogenic with a VDA and investigates carboplatin/
paclitaxel/bevacizumab  fosbretabulin in nonsquamous
NSCLC.
Dr. Leonardo Nicacio discussed CYT997, an orally
bioavailable VDA thatis similar to fosbretabulin and is a
tubulin de- polymerizing agent. Phase I studies with this
agent have been completed, and it is currently being tested in
a single-arm phase II combination study in relapsed glioblas-
toma multiforme. The oral formulation of the drug makes it
particularly attractive and amenable to metronomic and/or
bolus dosing. Phase I and II studies in NSCLC are in
development.
Dr. Harry Drabkin discussed the role of secreted sema-
phorins, specifically SEMA3F, and neuropilin (NRP) in the
pathogenesis of lung cancer. Among its other roles, NRP is
present in endothelial cells and mediates angiogenesis during
development in lung cells. It functions as a receptor for both
VEGF and other growth factors, such as SEMA3F. Never-
theless, binding of VEGF and SEMA3F to NRP leads to
opposite effects downstream; when NRP forms a complex
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with VEGF, it promotes angiogenesis, cell migration, and
tumorigenicity, whereas when it complexes with SEMA3F,
tumorigenesis is inhibited. In vitro studies have suggested a
role for combined anti-VEGF, pro-SEMA3F therapy, which
may provide another potential therapeutic approach in the
treatment of lung cancer.10
CONCLUSION AND FUTURE DIRECTIONS
VDAs represent an exciting new class of drugs that
target the existing tumor vasculature, causing tumor necrosis.
Phase II testing of VDAs in NSCLC has yielded promising
safety and efficacy data, and data from ongoing phase III
studies with these agents are eagerly awaited. As additional
data from preclinical and clinical trials testing VDAs emerge,
it is hoped that new insights into tumor angiogenesis will
follow, which will provide the basis for further drug devel-
opment in the targeting of established tumor vasculature.
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